Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>CROI</strong> 2013 Session 16<br />
b Monday, 1:30-2:30 pm; Ballroom 1-2<br />
Session 16–Themed Discussion<br />
(see Session 133 on Tuesday for corresponding Poster Abstracts)<br />
Statin Use and HIV: How Sweet Is It?<br />
Discussants:<br />
Steven Grinspoon, Massachusetts Gen Hosp, Boston, US<br />
Priscilla Hsue, Univ of California, San Francisco, US<br />
764 Statin Therapy and Mortality in HIV + Individuals:<br />
A Danish Nationwide Population-based Cohort Study<br />
Line Rasmussen* 1 , G Kronborg 2 , C Larsen 3 , C Pedersen 1 , J Gerstoft 4 ,<br />
and N Obel 4<br />
1 Odense Univ Hosp, Denmark;; 2 Copenhagen Univ Hosp, Hvidovre,<br />
Denmark;; 3 Aarhus Univ Hosp, Skejby, Denmark;; and 4 Copenhagen Univ<br />
Hosp, Rigshospitalet, Denmark<br />
765 Impact of Statin Exposure on Mortality and<br />
Non-AIDS Complications in HIV Patients on HAART<br />
Henning Drechsler* 1,2 , S Zhang 2 , N Maalouf 2 , J Cutrell 2 , P Tebas 3 ,<br />
and R Bedimo 1,2<br />
1 VA North Texas Hlth Care System, Dallas, US;; 2 Univ of Texas Southwestern<br />
Med Ctr, Dallas, US;; and 3 Univ of Pennsylvania, Philadelphia, US<br />
766 Association between Statin Use and Type-2 Diabetes<br />
Mellitus Occurrence among HIV-1 + Patients<br />
Receiving ART<br />
Vincenzo Spagnuolo* 1 , L Galli 1 , A Poli 1 , S Salpietro 1 , N Gianotti 1 ,<br />
P Piatti 1 , C Vinci 1 , E Carini 1 , A Lazzarin 1,2 , and A Castagna 1<br />
1 San Raffaele Sci Inst, Milan, Italy and 2 Univ Vita-Salute San Raffaele,<br />
Milan, Italy<br />
767 Statin Use Is Associated with Incident Diabetes<br />
Mellitus among Patients in the HIV Outpatient<br />
Study<br />
Kenneth Lichtenstein* 1 , R Debes 2 , K Wood 2 , S Bozzette 2,3 , K Buchacz 4 ,<br />
J Brooks 4 , and HIV Outpatient Study Investigators<br />
1 Natl Jewish Hlth, Denver, CO, US;; 2 Cerner Corp, Kansas City, MO, US;;<br />
3 Univ of California, San Diego, US;; and 4 CDC, Atlanta, GA, US<br />
C Monday, 2:30-4 pm; Hall B2<br />
Poster Abstracts<br />
(see full session listings starting on page 24)<br />
Session 53. HIV Persistence, Reservoirs, and Viremic Control<br />
Session 55. Envelope/Entry/Tropism/Transmission<br />
Session 58. Assembly–Putting It All Together<br />
Session 59. Restriction Factors: Old and New<br />
Session 64. HIV Compartments<br />
Session 67. HIV Infection Models<br />
Session 71. Immune Restoration<br />
Session 73. Immune Activation/Function in HIV Infection<br />
Session 74. Immune Activation, T Cell Homeostasis, and Therapy<br />
Session 75. Mucosal Factors in HIV Transmission and Infection<br />
Session 77. HIV Compartmentalization and Evolution on Therapy<br />
Session 84. Progressive Multifocal Leukoencephalopathy and Other<br />
Central Nervous System Infections<br />
Session 85. Central Nervous System Penetration, ART Intensification,<br />
and Cerebrospinal Fluid Escape<br />
Session 86. ART, Neurocognitive Outcomes, and New Central Nervous<br />
System-targeted Therapies<br />
Session 87. Central Nervous System Viral Evolution and<br />
Compartmentalization<br />
Session 95. Mining Sequence Data to Understand Transmission and<br />
Disease<br />
Session 96. Transmission Clusters<br />
Session 98. Within-patient Diversity Compartmentalization, Dual<br />
Infection, and Recombination<br />
Session 100. ARV Pharmacogenetics: Metabolism, Drug Interactions,<br />
and Response<br />
Session 101. ARV Drug Exposure, Safety, and Efficacy<br />
Session 105. New ARV Agents<br />
Session 106. Randomized Trials of ART: A Potpourri<br />
Session 118. Hepatic Injury and Fibrosis<br />
Session 119. Laboratory Assessment and Imaging of Hepatic Injury<br />
Session 120. Hepatitis E Virus<br />
Session 121. Hepatitis B Virus<br />
Session 128. HIV-associated Malignancies: Miscellaneous<br />
Session 130. Cardiovascular Disease: Predicting Risk and Monitoring<br />
Outcomes<br />
Session 131. Endothelial Dysfunction in HIV Infection<br />
Session 132. Vascular Imaging and Subclinical Atherosclerosis<br />
Session 141. Diabetes, Metabolic Syndrome, and Vitamin D Deficiency<br />
Session 143. Bone Loss: Risk Factors and Pathogenesis<br />
Session 144. ART and Bone Disease<br />
Session 150. Cryptococcal Infections<br />
Session 151. Herpes Zoster<br />
Session 152. Cytomegalovirus–Host Pathogen Interactions<br />
Session 153. Syphilis: Not Gone, Not Forgotten<br />
Session 154. Opportunistic Infections and Other Novel Pathogens<br />
Session 155. Vaccines: TB, Pneumococcus, and Influenza<br />
Session 156. HIV Shedding and Impact of Infection on Immune Cells in<br />
Women<br />
Session 161. HIV Testing and ARV Drug Resistance during Pregnancy<br />
Session 162. ART, Viral Suppression, and MTCT<br />
Session 170. Incidence and Prevention of PMTCT-associated Drug<br />
Resistance<br />
Session 171. New HIV Infections among Children in the US<br />
Session 172. ART Initiation and Immune Reconstitution Inflammatory<br />
Syndrome among Infants and Children<br />
Session 173. ART Strategies and Outcomes among Children<br />
Session 174. Cost and Cost-effectiveness of ART and Monitoring<br />
Strategies in Children<br />
Session 178. Characteristics of Youth with HIV<br />
Session 180. ARV Pharmacokinetics in Children<br />
Session 183. Preclinical Studies of Topical ARV for Prevention<br />
Session 187. Voluntary Medical Male Circumcision<br />
Session 190. The Cascade of Care<br />
Session 191. Engagement and Retention in Care<br />
Session 197. Performance and Innovation in ART <strong>Program</strong>s in RLS<br />
<strong>Program</strong> 7<br />
Monday<br />
March 4 Oral Sessions
Change language